Issuance Price. The 2030 Notes shall be issued at a price to the public of 99.898% of the principal amount of such series and the 2050 Notes shall be issued at a price to the public of 99.715% of the principal amount of such series, plus, in each case, accrued interest, if any, from August 12, 2020 to the Original Issue Date (as defined in the Note of the applicable series).
Appears in 1 contract
Sources: First Supplemental Indenture (Regeneron Pharmaceuticals, Inc.)
Issuance Price. The Notes due 2030 Notes shall be issued at a price to the public of 99.89899.973% of the principal amount of such series Series and the Notes due 2050 Notes shall be issued at a price to the public of 99.71599.174% of the principal amount of such seriesSeries, plus, in each case, accrued interest, if any, from August 12April 30, 2020 to the Original Issue Date (as defined in the Note of the applicable seriesSeries).
Appears in 1 contract
Issuance Price. The 2030 Notes due 2031 shall be issued at a price to the public of 99.89899.981% of the principal amount of such series and Series, the 2050 Notes due 2035 shall be issued at a price to the public of 99.71599.924% of the principal amount of such seriesSeries and the Notes due 2055 shall be issued at a price to the public of 99.657% of the principal amount of such Series, plus, in each case, accrued interest, if any, from August May 12, 2020 2025 to the Original Issue Date (as defined in the Note of the applicable seriesSeries).
Appears in 1 contract